EGFR and non-small cell lung carcinoma: 13, 2007) for treatment of advanced or metastatic breast cancer.11,12 However, due to the drug resistance observed by the targeted first generation reversible EGFR (epidermal growth factor receptor) drugs 1–3, by many patients, the second generation irreversible EGFR inhibitors were developed.13 Of which, Afatinib (Gilotrif) 4 and Dacomitinib (Vizimpro) 5 were approved for treatment of metastatic NSCLC (FDA on July 12, 2013 and Sept.